WallStreetZenWallStreetZen

NASDAQ: PGEN
Precigen Inc Stock

$1.64+0.10 (+6.49%)
Updated Jul 11, 2024
PGEN Price
$1.64
Fair Value Price
-$0.05
Market Cap
$413.97M
52 Week Low
$0.84
52 Week High
$1.88
P/E
-4.21x
P/B
4.27x
P/S
66.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.44M
Earnings
-$96.91M
Gross Margin
-4.2%
Operating Margin
-1,786.98%
Profit Margin
-1,781.7%
Debt to Equity
0.39
Operating Cash Flow
-$63M
Beta
1.61
Next Earnings
Aug 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

PGEN Overview

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PGEN ($1.64) is overvalued by 3,255.04% relative to our estimate of its Fair Value price of -$0.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PGEN ($1.64) is not significantly undervalued (3,255.04%) relative to our estimate of its Fair Value price of -$0.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PGEN due diligence checks available for Premium users.

Be the first to know about important PGEN news, forecast changes, insider trades & much more!

PGEN News

Valuation

PGEN fair value

Fair Value of PGEN stock based on Discounted Cash Flow (DCF)
Price
$1.64
Fair Value
-$0.05
Undervalued by
3,255.04%
PGEN ($1.64) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PGEN ($1.64) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PGEN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.21x
Industry
-14.46x
Market
31.84x

PGEN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.27x
Industry
6.37x
PGEN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PGEN's financial health

Profit margin

Revenue
$1.1M
Net Income
-$23.7M
Profit Margin
-2,228.9%
PGEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PGEN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$134.8M
Liabilities
$37.8M
Debt to equity
0.39
PGEN's short-term assets ($49.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PGEN's short-term assets ($49.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PGEN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$14.1M
Investing
$24.0M
Financing
$0.0
PGEN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PGEN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
PGEN$413.97M+6.49%-4.21x4.27x
KYTX$414.34M+13.59%N/A1.15x
AURA$410.22M+11.74%-4.45x1.96x
AVXL$418.13M+6.93%-9.69x3.10x
OCS$418.84M+1.79%-6.87x4.82x

Precigen Stock FAQ

What is Precigen's quote symbol?

(NASDAQ: PGEN) Precigen trades on the NASDAQ under the ticker symbol PGEN. Precigen stock quotes can also be displayed as NASDAQ: PGEN.

If you're new to stock investing, here's how to buy Precigen stock.

What is the 52 week high and low for Precigen (NASDAQ: PGEN)?

(NASDAQ: PGEN) Precigen's 52-week high was $1.88, and its 52-week low was $0.84. It is currently -12.77% from its 52-week high and 96.41% from its 52-week low.

How much is Precigen stock worth today?

(NASDAQ: PGEN) Precigen currently has 252,419,690 outstanding shares. With Precigen stock trading at $1.64 per share, the total value of Precigen stock (market capitalization) is $413.97M.

Precigen stock was originally listed at a price of $24.73 in Aug 8, 2013. If you had invested in Precigen stock at $24.73, your return over the last 10 years would have been -93.37%, for an annualized return of -23.76% (not including any dividends or dividend reinvestments).

How much is Precigen's stock price per share?

(NASDAQ: PGEN) Precigen stock price per share is $1.64 today (as of Jul 11, 2024).

What is Precigen's Market Cap?

(NASDAQ: PGEN) Precigen's market cap is $413.97M, as of Jul 12, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Precigen's market cap is calculated by multiplying PGEN's current stock price of $1.64 by PGEN's total outstanding shares of 252,419,690.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.